These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: critical role of IFN-alpha. Satthaporn S; Aloysius MM; Robins RA; Verma C; Chuthapisith S; McKechnie AJ; El-Sheemy M; Vassanasiri W; Valerio D; Clark D; Jibril JA; Eremin O BMC Immunol; 2008 Jun; 9():32. PubMed ID: 18588665 [TBL] [Abstract][Full Text] [Related]
64. Side effects of interferon-alpha therapy. Sleijfer S; Bannink M; Van Gool AR; Kruit WH; Stoter G Pharm World Sci; 2005 Dec; 27(6):423-31. PubMed ID: 16341948 [TBL] [Abstract][Full Text] [Related]
65. Viral protein VP4 is a target of human antibodies enhancing coxsackievirus B4- and B3-induced synthesis of alpha interferon. Chehadeh W; Lobert PE; Sauter P; Goffard A; Lucas B; Weill J; Vantyghem MC; Alm G; Pigny P; Hober D J Virol; 2005 Nov; 79(22):13882-91. PubMed ID: 16254324 [TBL] [Abstract][Full Text] [Related]
66. Role of cytokines in the pathogenesis of autoimmune diabetes mellitus. Rabinovitch A; Suarez-Pinzon WL Rev Endocr Metab Disord; 2003 Sep; 4(3):291-9. PubMed ID: 14501180 [No Abstract] [Full Text] [Related]
67. Detection of anti-HAV antibody with dot immunogold filtration assay. Shao ZJ; Xu DZ; Yan YP; Li JH; Zhang JX; Zhang ZY; Pan BR World J Gastroenterol; 2003 Jul; 9(7):1508-11. PubMed ID: 12854152 [TBL] [Abstract][Full Text] [Related]
68. Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. Fabbri C; Jaboli MF; Giovanelli S; Azzaroli F; Pezzoli A; Accogli E; Liva S; Nigro G; Miracolo A; Festi D; Colecchia A; Montagnani M; Roda E; Mazzella G World J Gastroenterol; 2003 Jul; 9(7):1487-90. PubMed ID: 12854147 [TBL] [Abstract][Full Text] [Related]
70. Naturally acquired human immune responses against Helicobacter pylori and implications for vaccine development. Zevering Y; Jacob L; Meyer TF Gut; 1999 Sep; 45(3):465-74. PubMed ID: 10446121 [No Abstract] [Full Text] [Related]
71. Type I interferon-mediated stimulation of T cells by CpG DNA. Sun S; Zhang X; Tough DF; Sprent J J Exp Med; 1998 Dec; 188(12):2335-42. PubMed ID: 9858519 [TBL] [Abstract][Full Text] [Related]
72. DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen. Sun S; Kishimoto H; Sprent J J Exp Med; 1998 Apr; 187(7):1145-50. PubMed ID: 9529331 [TBL] [Abstract][Full Text] [Related]
73. Intercellular adhesion molecule-1 is necessary but not sufficient to activate CD4+ T cells. Discovery of a novel costimulator on kidney tubule cells. Hagerty DT J Immunol; 1996 May; 156(10):3652-9. PubMed ID: 8621899 [TBL] [Abstract][Full Text] [Related]
74. Interference with islet-specific homing of autoreactive T cells: an emerging therapeutic strategy for type 1 diabetes. Savinov AY; Burn P Drug Discov Today; 2010 Jul; 15(13-14):531-9. PubMed ID: 20685342 [TBL] [Abstract][Full Text] [Related]
75. IFN-alpha induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2. Chakrabarti D; Hultgren B; Stewart TA J Immunol; 1996 Jul; 157(2):522-8. PubMed ID: 8752897 [TBL] [Abstract][Full Text] [Related]
76. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production. Schweitzer AN; Sharpe AH J Immunol; 1998 Sep; 161(6):2762-71. PubMed ID: 9743334 [TBL] [Abstract][Full Text] [Related]
77. Autoimmunity without diabetes in transgenic mice expressing beta cell-specific CD86, but not CD80: parameters that trigger progression to diabetes. Guerder S; Eynon EE; Flavell RA J Immunol; 1998 Sep; 161(5):2128-40. PubMed ID: 9725204 [TBL] [Abstract][Full Text] [Related]